Maxcyte Share Price Today
(NASDAQ: MXCT)

Name: Maxcyte Share Price Today (NASDAQ: MXCT) - Maxcyte Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Maxcyte share price is $3.54 & ₹308.21 as on 6 Mar 2025, 2.30 'hrs' IST

$3.54

▲

0.11

(3.21%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Maxcyte share price in Dollar and Rupees. Guide to invest in Maxcyte stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Maxcyte, along with analyst recommendations, forecasts, and comprehensive financials.

Maxcyte share price movements

Today's Low: $3.44
Today's High: $3.57
$3.54
2.82%
Downside
Day's Volatility :3.64%
Upside
0.84%
52 Weeks Low: $3.17
52 Weeks High: $5.26
$3.54
10.59%
Downside
52 Weeks Volatility :39.83%
Upside
32.7%

Maxcyte (MXCT) Returns

Period	Maxcyte Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-1.12%	3.7%	0.0%
6 Months	-10.61%	-2.8%	0.0%
1 Year	-11.5%	2.5%	0.0%
3 Years	-39.9%	12.9%	-11.6%

Maxcyte (MXCT) Key Statistics

in dollars & INR

Previous Close	$3.43
Open	$3.44
Today's High	$3.57
Today's Low	$3.44
Market Capitalization	$361.8M
Today's Volume	$856.4K
52 Week High	$5.26
52 Week Low	$3.165
Revenue TTM	$45.6M
EBITDA	$-42.0M
Earnings Per Share (EPS)	$-0.34
Profit Margin	-78.37%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-16.0%

How to invest in Maxcyte Stock (MXCT) from India?

It is very easy for Indian residents to invest directly in Maxcyte from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Maxcyte stock in both Indian Rupees (INR) and US Dollars (USD). Search for Maxcyte or MXCT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Maxcyte or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Maxcyte shares which would translate to 0.246 fractional shares of Maxcyte as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Maxcyte, in just a few clicks!

Returns in Maxcyte (MXCT) for Indian investors in Rupees

The Maxcyte stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Maxcyte investment value today

Current value as on today

₹93,565

Returns

₹6,435

(-6.44%)

Returns from Maxcyte Stock

₹11,500 (-11.5%)

Dollar Returns

₹5,065 (+5.06%)

Indian investors sentiment towards Maxcyte (MXCT)

-86%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Maxcyte Stock from India on INDmoney has decreased by -86% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Maxcyte

Cadian Capital Management LP
8.86%
BlackRock Inc
7.61%
Vanguard Group Inc
5.15%
Vitruvian Partners
4.78%
Morgan Stanley - Brokerage Accounts
4.18%
Mirabella Financial Services LLP
3.51%

Analyst Recommendation on Maxcyte

Buy

92%Buy

7%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Maxcyte(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Maxcyte Stock (MXCT)

What analysts predicted

Upside of 161.3%

Target:

$9.25

Current:

$3.54

Insights on Maxcyte Stock (Ticker Symbol: MXCT)

Price Movement
In the last 7 days, MXCT stock has moved up by 3.2%
Decreasing Revenue
Revenue is down for the last 4 quarters, 15.66M → 8.16M (in $), with an average decrease of 19.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -9.37M → -11.55M (in $), with an average decrease of 23.3% per quarter
MXCT vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 55.3% return, outperforming this stock by 66.8%
MXCT vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 138.2% return, outperforming this stock by 178.1%
Price to Sales
ForMXCT every $1 of sales, investors are willing to pay $8.1, whereas for Boston Scientific Corp., the investors are paying $9.2 for every $1 of sales.

MXCT Maxcyte Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$16.7M	↑ 19.18%
Net Income	$-8.9M	↓ 10.57%
Net Profit Margin	-53.21%	↑ 17.7%

	FY19	Y/Y Change
Revenue	$21.6M	↑ 29.72%
Net Income	$-13.6M	↑ 53.07%
Net Profit Margin	-62.79%	↓ 9.58%

	FY20	Y/Y Change
Revenue	$26.2M	↑ 21.04%
Net Income	$-12.6M	↓ 6.88%
Net Profit Margin	-48.31%	↑ 14.48%

	FY21	Y/Y Change
Revenue	$33.9M	↑ 29.52%
Net Income	$-20.1M	↑ 59.2%
Net Profit Margin	-59.38%	↓ 11.07%

	FY22	Y/Y Change
Revenue	$44.3M	↑ 30.59%
Net Income	$-19.8M	↓ 1.72%
Net Profit Margin	-44.69%	↑ 14.69%

	FY23	Y/Y Change
Revenue	$41.3M	↓ 6.72%
Net Income	$-37.9M	↑ 91.71%
Net Profit Margin	-91.85%	↓ 47.16%

	Q2 FY23	Q/Q Change
Revenue	$9.0M	↑ 5.44%
Net Income	$-10.5M	↑ 22.43%
Net Profit Margin	-116.25%	↓ 16.14%

	Q3 FY23	Q/Q Change
Revenue	$8.0M	↓ 11.48%
Net Income	$-11.3M	↑ 7.04%
Net Profit Margin	-140.57%	↓ 24.32%

	Q4 FY23	Q/Q Change
Revenue	$15.7M	↑ 95.71%
Net Income	$-5.3M	↓ 53.1%
Net Profit Margin	-33.68%	↑ 106.89%

	Q1 FY24	Q/Q Change
Revenue	$11.3M	↓ 27.6%
Net Income	$-9.5M	↑ 80.52%
Net Profit Margin	-83.99%	↓ 50.31%

	Q2 FY24	Q/Q Change
Revenue	$10.4M	↓ 8.05%
Net Income	$-9.4M	↓ 1.59%
Net Profit Margin	-89.89%	↓ 5.9%

	Q3 FY24	Q/Q Change
Revenue	$8.2M	↓ 21.72%
Net Income	$-11.6M	↑ 23.27%
Net Profit Margin	-141.56%	↓ 51.67%

	FY18	Y/Y Change
Profit	$14.8M	↑ 18.31%

	FY19	Y/Y Change
Profit	$19.1M	↑ 28.96%

	FY20	Y/Y Change
Profit	$23.4M	↑ 22.39%

	FY21	Y/Y Change
Profit	$30.2M	↑ 29.25%

	FY22	Y/Y Change
Profit	$39.2M	↑ 29.48%

	FY23	Y/Y Change
Profit	$36.5M	↓ 6.68%

	Q2 FY23	Q/Q Change
Profit	$7.7M	↑ 1.19%

	Q3 FY23	Q/Q Change
Profit	$7.2M	↓ 5.95%

	Q4 FY23	Q/Q Change
Profit	$13.0M	↑ 80.69%

	Q1 FY24	Q/Q Change
Profit	$8.9M	↓ 31.92%

	Q2 FY24	Q/Q Change
Profit	$7.9M	↓ 10.87%

	Q3 FY24	Q/Q Change
Profit	$6.2M	↓ 21.13%

	FY18	Y/Y Change
Operating Cash Flow	$-10.5M	↑ 8.37%
Investing Cash Flow	$-3.8M	↑ 528.69%
Financing Cash Flow	$226.8K	↓ 99.05%

	FY19	Y/Y Change
Operating Cash Flow	$-8.8M	↓ 16.07%
Investing Cash Flow	$454.5K	↓ 111.86%
Financing Cash Flow	$12.3M	↑ 5328.04%

	FY20	Y/Y Change
Operating Cash Flow	$-8.8M	↓ 0.23%
Investing Cash Flow	$-16.6M	↓ 3747.52%
Financing Cash Flow	$28.9M	↑ 134.79%

	FY21	Y/Y Change
Operating Cash Flow	$-10.7M	↑ 21.61%
Investing Cash Flow	$-195.0M	↑ 1076.34%
Financing Cash Flow	$234.7M	↑ 712.05%

	FY22	Y/Y Change
Operating Cash Flow	$-14.8M	↑ 38.42%
Investing Cash Flow	$-24.8M	↓ 87.27%
Financing Cash Flow	$2.9M	↓ 98.77%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-10.1M	↑ 133.66%
Investing Cash Flow	$26.7M	↓ 10.0%
Financing Cash Flow	$156.7K	↓ 89.24%

Maxcyte Technicals Summary

Sell

Neutral

Buy

Maxcyte is currently in a neutral trading position according to technical analysis indicators.

Maxcyte (MXCT) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Maxcyte Inc	-21.33%	-10.61%	-11.5%	-39.9%	-66.16%
Medtronic Plc	3.4%	5.22%	9.95%	-11.8%	1.8%
Edwards Lifesciences Corp.	2.13%	10.35%	-17.53%	-32.76%	14.39%
Boston Scientific Corp.	1.13%	28.68%	55.31%	146.09%	207.16%
Stryker Corporation	0.84%	10.53%	11.46%	56.15%	129.21%
Abbott Laboratories	6.67%	21.76%	15.39%	15.86%	78.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Maxcyte Inc	NA	NA	NA	-0.41	-0.16	-0.11	NA	2.03
Medtronic Plc	28.71	28.71	1.91	5.45	0.08	0.05	0.03	38.49
Edwards Lifesciences Corp.	31.13	31.13	5.57	2.45	0.17	0.08	NA	16.99
Boston Scientific Corp.	84.24	84.24	1.87	2.86	0.09	0.05	NA	14.76
Stryker Corporation	50.77	50.77	2.91	13.49	0.15	0.07	0.01	54.1
Abbott Laboratories	18.34	18.34	2.52	5.15	0.31	0.06	0.02	27.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Maxcyte Inc	Buy	$361.8M	-66.16%	NA	-78.37%
Medtronic Plc	Buy	$119.3B	1.8%	28.71	12.83%
Edwards Lifesciences Corp.	Buy	$42.8B	14.39%	31.13	76.75%
Boston Scientific Corp.	Buy	$152.9B	207.16%	84.24	11.07%
Stryker Corporation	Buy	$148.8B	129.21%	50.77	13.25%
Abbott Laboratories	Buy	$238.6B	78.8%	18.34	31.95%

About Maxcyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Organization	Maxcyte
Employees	143
CEO	Mr. Maher Masoud
Industry	Healthcare

Management People of Maxcyte

Name	Title
Mr. Maher Masoud	President, CEO & Executive Director
Mr. Douglas Arthur Doerfler	Founder
Mr. Douglas J. Swirsky CFA, CPA	Chief Financial Officer
Mr. Jay Gelfman	Senior Vice President of Operations
Mr. Ronald Evan Holtz CPA, Ph.D.	Executive Vice President of Administration
Mr. David Sandoval	Senior Vice President, General Counsel & Corporate Secretary
Mr. Jack Horgan	Vice President of Corporate Development
Ms. Ana-Paula Martins Fernandes	Senior Vice President of Global Sales
Ms. Jill Mayer	Senior Vice President of Human Resources
Dr. J. Stark Thompson Ph.D.	Consultant

Important FAQs about investing in MXCT Stock from India :

What is Maxcyte share price today?

Maxcyte share price today stands at $3.54, Open: $3.44 ; Previous Close: $3.43 ; High: $3.57 ; Low: $3.44 ; 52 Week High: $5.26 ; 52 Week Low: $3.17.

The stock opens at $3.44, after a previous close of $3.43. The stock reached a daily high of $3.57 and a low of $3.44, with a 52-week high of $5.26 and a 52-week low of $3.17.

Can Indians buy Maxcyte shares?

Yes, Indians can invest in the Maxcyte (MXCT) from India.

With INDmoney, you can buy Maxcyte at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Maxcyte at zero transaction cost.

How can I buy Maxcyte shares from India?

It is very easy to buy Maxcyte from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Maxcyte (MXCT) be purchased?

Yes, you can buy fractional shares of Maxcyte with INDmoney app.

What are the documents required to start investing in Maxcyte stocks?

To start investing in Maxcyte, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.